{"id":10196,"date":"2026-02-09T16:17:57","date_gmt":"2026-02-09T16:17:57","guid":{"rendered":"https:\/\/www.urologist.org\/new\/?page_id=10196"},"modified":"2026-02-11T15:29:32","modified_gmt":"2026-02-11T15:29:32","slug":"research-open-studies","status":"publish","type":"page","link":"https:\/\/www.urologist.org\/new\/research-open-studies\/","title":{"rendered":"Research Open Studies"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
\n\t\t\t<\/i>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Largest Urology Research Department<\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Advancing Urologic Care<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
\n\t\t\t<\/i>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Explore Our Active Research Studies<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

CORE-008<\/u><\/b><\/p>

Brief Summary<\/b><\/p><\/div>

This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer<\/p><\/div>

ClinicalTrials.gov ID\u00a0NCT06567743<\/p>

https:\/\/clinicaltrials.gov\/study\/NCT06567743?term=core-008&rank=2#more-information<\/a><\/p>

PIVOT-006<\/u><\/b><\/p>

Brief Summary:
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.<\/p><\/div>

ClinicalTrials.gov ID\u00a0NCT06111235<\/p>

https:\/\/clinicaltrials.gov\/study\/NCT06111235?term=pivot-006&rank=1<\/a><\/p>

SunRISe-5<\/u><\/b><\/p>

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Gu\u00e9rin (BCG)<\/p>

ClinicalTrials.gov ID\u00a0NCT06211764<\/p>

https:\/\/clinicaltrials.gov\/study\/NCT06211764?term=sunrise-5&rank=1<\/a><\/p>

MoonRISe-1<\/u><\/b><\/p>

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer<\/b><\/u><\/p>

ClinicalTrials.gov ID NCT06319820<\/p>

https:\/\/clinicaltrials.gov\/study\/NCT06319820?term=moonrise-1&limit=10&sort=@relevance&rank=1<\/a><\/p>

MoonRISe-3<\/u><\/b><\/p>

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer<\/b><\/u><\/p>

ClinicalTrials.gov ID NCT06919965<\/p>

https:\/\/clinicaltrials.gov\/study\/NCT06919965?term=moonrise-3&limit=10&sort=@relevance&rank=1<\/a><\/p>

QUILT-2.005<\/u><\/b><\/p>

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer<\/p>

ClinicalTrials.gov ID NCT02138734<\/p>

https:\/\/clinicaltrials.gov\/study\/NCT02138734?term=CA%20ALT-803-01-14&limit=10&sort=@relevance&rank=2<\/a><\/p>

PATAPSCO<\/u><\/b><\/p>

BCG in Combination With Durvalumab in Adult BCG-na\u00efve, High-risk NMIBC Participants\u00a0<\/p>

ClinicalTrials.gov ID NCT05943106<\/p>

https:\/\/clinicaltrials.gov\/study\/NCT05943106?term=patapsco&limit=10&sort=@relevance&rank=1<\/a><\/p>

<\/b><\/u>SURF303<\/u><\/b>
<\/b><\/p>

Phase 2A\/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma<\/p>

ClinicalTrials.gov ID\u00a0NCT07265947<\/p>

https:\/\/clinicaltrials.gov\/study\/NCT07265947?term=tyr300-203&limit=10&sort=@relevance&rank=1<\/a>
<\/b><\/p>

SCORE<\/u>
<\/b><\/p>

A prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors. The collected specimens and information will be used to evaluate the clinical performance of Natera’s molecular residual disease (MRD) testing across multiple cancer types. The study aims to assess the ability of Natera’s assays to detect circulating tumor DNA (ctDNA) as a marker for disease recurrence and treatment response<\/p>

ClinicalTrials.gov ID NCT07318051<\/p>

https:\/\/clinicaltrials.gov\/study\/NCT07318051?term=score%20natera&limit=10&sort=@relevance&rank=1<\/a><\/p>

For more information about our research department, please contact us at\u00a0research@urologist.org<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Public IBC Meeting Minutes<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

June 23, 2025<\/b><\/p>

Sabai IBC Meeting Minutes<\/a><\/p>

\u00a0<\/p><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Largest Urology Research Department Advancing Urologic Care Explore Our Active Research Studies CORE-008 Brief Summary This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer ClinicalTrials.gov ID\u00a0NCT06567743 https:\/\/clinicaltrials.gov\/study\/NCT06567743?term=core-008&rank=2#more-information PIVOT-006 Brief Summary:This is a Phase 3, open-label, randomized trial designed to […]<\/p>\n","protected":false},"author":4,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"full-width-container","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-10196","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.urologist.org\/new\/wp-json\/wp\/v2\/pages\/10196","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.urologist.org\/new\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.urologist.org\/new\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.urologist.org\/new\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.urologist.org\/new\/wp-json\/wp\/v2\/comments?post=10196"}],"version-history":[{"count":19,"href":"https:\/\/www.urologist.org\/new\/wp-json\/wp\/v2\/pages\/10196\/revisions"}],"predecessor-version":[{"id":10221,"href":"https:\/\/www.urologist.org\/new\/wp-json\/wp\/v2\/pages\/10196\/revisions\/10221"}],"wp:attachment":[{"href":"https:\/\/www.urologist.org\/new\/wp-json\/wp\/v2\/media?parent=10196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}